How much revenue did Novacyt generate this year?
Novacyt has achieved a revenue of 72.92 M GBP this year.
Novacyt Revenue 2024
Novacyt Revenue
72.92 M GBP
Ticker
ALNOV.PA
ISIN
FR0010397232
WKN
A12CFH
In 2024, Novacyt's sales reached 72.92 M GBP, a 529.74% difference from the 11.58 M GBP sales recorded in the previous year.
The Novacyt Revenue history
| YEAR | REVENUE (undefined GBP) | GROSS MARGIN (%) |
|---|---|---|
| 2025e | - | - |
| 2024e | - | - |
| 2023 | - | - |
| 2022 | - | - |
| 2021 | - | - |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | - | - |
| 2017 | - | - |
| 2016 | - | - |
| 2015 | - | - |
| 2014 | - | - |
| 2013 | - | - |
| 2012 | - | - |
| 2011 | - | - |
| 2010 | - | - |
| 2009 | - | - |
| 2008 | - | - |
Novacyt Revenue, EBIT, Net Income FR0010397232 · A12CFH
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Novacyt, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novacyt from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novacyt’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Novacyt. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Novacyt’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Novacyt’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novacyt’s growth potential.
Novacyt Revenue, EBIT and net profit per share
| Date | Novacyt Revenue | Novacyt EBIT | Novacyt Net Income |
|---|---|---|---|
| 2025e | 0 undefined | 0 undefined | 0 undefined |
| 2024e | 0 undefined | 0 undefined | 0 undefined |
| 2023 | 0 undefined | 0 undefined | 0 undefined |
| 2022 | 0 undefined | 0 undefined | 0 undefined |
| 2021 | 0 undefined | 0 undefined | 0 undefined |
| 2020 | 0 undefined | 0 undefined | 0 undefined |
| 2019 | 0 undefined | 0 undefined | 0 undefined |
| 2018 | 0 undefined | 0 undefined | 0 undefined |
| 2017 | 0 undefined | 0 undefined | 0 undefined |
| 2016 | 0 undefined | 0 undefined | 0 undefined |
| 2015 | 0 undefined | 0 undefined | 0 undefined |
| 2014 | 0 undefined | 0 undefined | 0 undefined |
| 2013 | 0 undefined | 0 undefined | 0 undefined |
| 2012 | 0 undefined | 0 undefined | 0 undefined |
| 2011 | 0 undefined | 0 undefined | 0 undefined |
| 2010 | 0 undefined | 0 undefined | 0 undefined |
| 2009 | 0 undefined | 0 undefined | 0 undefined |
| 2008 | 0 undefined | 0 undefined | 0 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 0 GBP | 0 GBP | 0 GBP |
| 2009 | 0 GBP | 0 GBP | 0 GBP |
| 2010 | 0 GBP | 0 GBP | 0 GBP |
| 2011 | 0 GBP | 0 GBP | 0 GBP |
| 2012 | 0 GBP | 0 GBP | 0 GBP |
| 2013 | 0 GBP | 0 GBP | 0 GBP |
| 2014 | 0 GBP | 0 GBP | 0 GBP |
| 2015 | 0 GBP | 0 GBP | 0 GBP |
| 2016 | 0 GBP | 0 GBP | 0 GBP |
| 2017 | 0 GBP | 0 GBP | 0 GBP |
| 2018 | 0 GBP | 0 GBP | 0 GBP |
| 2019 | 0 GBP | 0 GBP | 0 GBP |
| 2020 | 0 GBP | 0 GBP | 0 GBP |
| 2021 | 0 GBP | 0 GBP | 0 GBP |
| 2022 | 0 GBP | 0 GBP | 0 GBP |
| 2023 | 0 GBP | 0 GBP | 0 GBP |
| 2024e | 0 GBP | 0 GBP | 0 GBP |
| 2025e | 0 GBP | 0 GBP | 0 GBP |
Novacyt stock margins FR0010397232 · A12CFH
The Novacyt margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novacyt. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novacyt.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Novacyt's sales revenue. A higher gross margin percentage indicates that the Novacyt retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Novacyt's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Novacyt's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novacyt's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novacyt. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novacyt's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Novacyt Margin History
| Novacyt Gross margin | Novacyt Profit margin | Novacyt EBIT margin | Novacyt Profit margin |
|---|---|---|---|
| 2025e | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| 2011 | 0 % | 0 % | 0 % |
| 2010 | 0 % | 0 % | 0 % |
| 2009 | 0 % | 0 % | 0 % |
| 2008 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | 0 % | 0 % | 0 % |
| 2009 | 0 % | 0 % | 0 % |
| 2010 | 0 % | 0 % | 0 % |
| 2011 | 0 % | 0 % | 0 % |
| 2012 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2015 | 0 % | 0 % | 0 % |
| 2016 | 0 % | 0 % | 0 % |
| 2017 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2025e | 0 % | 0 % | 0 % |
Novacyt Aktienanalyse
What does Novacyt do?
Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Novacyt's Sales Figures
The sales figures of Novacyt originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Novacyt’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Novacyt's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Novacyt’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Novacyt stock
How much was the turnover of the company Novacyt compared to the previous year?
The revenue of Novacyt has increased by 529.74% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Novacyt?
The revenue of Novacyt is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Novacyt measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Novacyt so important for investors?
The revenue of Novacyt is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Novacyt pay?
Over the past 12 months, Novacyt paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novacyt is expected to pay a dividend of 0 GBP.
What is the dividend yield of Novacyt?
The current dividend yield of Novacyt is .
When does Novacyt pay dividends?
Novacyt pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novacyt?
Novacyt paid dividends every year for the past 0 years.
What is the dividend of Novacyt?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novacyt located?
Novacyt is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novacyt kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novacyt from 8/18/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/18/2024.
When did Novacyt pay the last dividend?
The last dividend was paid out on 8/18/2024.
What was the dividend of Novacyt in the year 2023?
In the year 2023, Novacyt distributed 0 GBP as dividends.
In which currency does Novacyt pay out the dividend?
The dividends of Novacyt are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novacyt
Our stock analysis for Novacyt Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
